• Email
  • Help

Questions & Answers

On 25 January 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Shingrix, intended for prophylaxis of herpes zoster. The applicant for this medicinal product is GlaxoSmithkline Biologicals SA.

Shingrix will be available as a powder and suspension liquid to be made into a suspension for injection. The active substance of Shingrix is varicella zoster virus glycoprotein E antigen (VZV gE) (ATC code: J07BK03). In Shingrix, VZV gE is combined with an adjuvant (AS01B), and is designed to induce antigen-specific cellular and humoral immune responses in individuals with pre-existing immunity against varicella zoster virus.

The benefits with Shingrix are its ability to significantly decrease the incidence of herpes zoster and consequently of post-herpetic neuralgia compared with placebo. The most common side effects are pain at the injection site, myalgia, fatigue and headache.

The full indication is: "Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in adults 50 years of age or older (see section 5.1). The use of Shingrix should be in accordance with official recommendations".

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Name Language First published Last updated
CHMP summary of positive opinion for Shingrix (English only) 2018-01-26  

Key facts

Product details for Shingrix
INN or common name

herpes zoster vaccine (recombinant, adjuvanted)

Therapeutic area Herpes Zoster
Active substance

varicella zoster virus glycoprotein E antigen

Date opinion adopted25/01/2018
Company name

GlaxoSmithkline Biologicals SA

Application typeInitial authorisation